Olfr847, also known as an olfactory receptor, is part of a vast and complex family of G-protein coupled receptors (GPCRs). These receptors are integral to the olfactory system, playing a critical role in odorant recognition and signal transduction. Olfr847, like other olfactory receptors, is characterized by its ability to bind specific odorant molecules, triggering a cascade of intracellular events that ultimately lead to the perception of smell. The functional mechanism of Olfr847 involves the binding of odorant molecules to the receptor, which then activates an associated G-protein. This G-protein, in turn, initiates a signaling pathway, often involving the production of cAMP or IP3, leading to a neuronal response that is relayed to the brain. Inhibiting Olfr847's activity, therefore, can be approached by targeting various aspects of this signaling cascade. Direct inhibitors of Olfr847 would typically be molecules that bind to the receptor's active site, preventing interaction with its natural ligands. However, given the vast diversity and specificity of olfactory receptors, finding direct inhibitors is a challenging task. Indirect inhibition, as explored through the chemical inhibitors listed earlier, targets various components of the signaling pathways associated with GPCRs in general, and by extension, could influence Olfr847.
The indirect inhibition of Olfr847 involves a strategic disruption or modulation of the intracellular signaling pathways triggered by the receptor's activation. Since GPCRs, including olfactory receptors, commonly utilize second messengers like cAMP, targeting enzymes involved in the synthesis or degradation of these messengers offers a potential inhibition mechanism. For example, chemicals that inhibit adenylate cyclase can reduce cAMP levels, thereby dampening the receptor's signaling. Similarly, phosphodiesterase inhibitors, which prevent cAMP breakdown, can also indirectly affect the receptor's function by altering intracellular signaling dynamics. Another approach to indirect inhibition focuses on the G-protein itself. G-proteins are pivotal in linking receptor activation to downstream effectors. Inhibitors targeting the G-protein subunits or their activators can disrupt the signaling pathway, thereby modulating the receptor's overall response. This mechanism is particularly relevant in the context of olfactory receptors, as they heavily rely on G-protein-mediated pathways for signal transduction.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Brefeldin A disrupts protein transport by inhibiting ADP-ribosylation factor (ARF), a GTPase involved in vesicle formation. This impedes cellular trafficking, indirectly affecting G-protein coupled receptors (GPCRs) like Olfr847 by disrupting their transport and signaling. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein is a tyrosine kinase inhibitor that also modulates the activity of GPCRs. By inhibiting downstream signaling pathways, such as those involving PI3K and MAPK, Genistein indirectly influences Olfr847's signal transduction. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor, affecting downstream Akt signaling. This action indirectly influences GPCR-mediated pathways, including those involving Olfr847, by modulating receptor internalization and downstream signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a MEK inhibitor, which impedes the MAPK/ERK pathway. By inhibiting this pathway, U0126 indirectly affects the function and expression of GPCRs like Olfr847, impacting their signaling processes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 specifically inhibits MEK, which is a part of the MAPK pathway. This results in altered GPCR signaling, indirectly impacting Olfr847's function by modulating its downstream signaling pathways. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. By modulating the MAPK pathway, it indirectly affects GPCR signaling, thereby influencing Olfr847's signaling and cellular response. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, a key regulator in cell growth and proliferation. This indirectly influences GPCR signaling pathways, including those associated with Olfr847, by altering cellular metabolic states and response mechanisms. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent PI3K inhibitor. It disrupts PI3K-dependent pathways, which indirectly affects GPCR-mediated signaling including that of Olfr847, by influencing receptor trafficking and downstream signaling. | ||||||
Gö 6976 | 136194-77-9 | sc-221684 | 500 µg | $223.00 | 8 | |
Go6976 is a protein kinase C inhibitor. By affecting PKC-mediated pathways, it indirectly alters GPCR signaling, thus impacting Olfr847's function and signaling efficiency. | ||||||
NF449 | 627034-85-9 | sc-478179 sc-478179A sc-478179B | 10 mg 25 mg 100 mg | $199.00 $460.00 $1479.00 | 1 | |
NF449 is a potent Gsα subunit inhibitor. By disrupting Gsα-mediated signaling, it indirectly influences GPCR activity, including Olfr847, affecting their cellular signaling processes. | ||||||